Great summary of the P1.
RCE looking very interesting now, and I am liking the quicker route to market (value) of UTI versus sepsis.
I also like the kidney health-tonic angle, haha. Almost too good to be true... But worth a very big gamble now.
We need burns results though. They are like a millstone around the RCE neck.
Ann: Phase I Clinical Trial Data Review Complete, page-4
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
53.0¢ |
Change
-0.010(1.85%) |
Mkt cap ! $122.7M | |||
| Open | High | Low | Value | Volume |
| 53.0¢ | 53.5¢ | 52.0¢ | $23.98K | 45.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 22231 | 53.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 54.0¢ | 34072 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| RCE (ASX) Chart |